Chemotherapy Induced Peripheral Neuropathy (CIPN): Neuroimmune Crosstalk and Inflammation in Chemotherapy-induced Peripheral Neuropathy
25m 58s
Chemotherapy-induced peripheral neuropathy (CIPN) is increasingly understood as a neuroimmune disorder rather than purely a direct neurotoxic effect. Preclinical studies highlight the role of innate immune activation—particularly through macrophages and cytokines—driven by sensory neuron injury and resulting in bidirectional neuroimmune crosstalk. However, translating these findings to patients remains challenging due to variability in cancer types, treatment regimens, and baseline immune status. The skin, once viewed merely as a site of nerve fiber loss, is now recognized as a dynamic neurocutaneous environment where cancer cells, immune cells, and epithelial stress contribute to inflammation and sensory dysfunction. While circulating biomarkers show potential, their clinical relevance is limited; instead, patient-specific phenotyping linked to localized tissue biology (e.g., skin biopsies) offers a more meaningful pathway for diagnosis and monitoring. Research is shifting toward integrated models that combine preclinical data with longitudinal clinical observations to identify distinct CIPN subtypes. Key advances will come from understanding how immune responses evolve over time—from acute injury to chronic symptoms—and developing targeted, stage-specific therapies that do not compromise cancer treatment efficacy. Ultimately, the field aims toward mechanism-informed, personalized approaches to CIPN care, enabling early prediction, prevention, and effective intervention based on individual patient biology.
[Music]
Welcome to the peripheral nerve podcast, the official podcast of the peripheral nerve society,
exploring topics in peripheral nerve disorders, awareness, education, and advocacy.
We are your host, Professor Sizana Park from the University of Sydney, Australia, and Dr. Paola
Batting from University of Milano Bicocca, Italy. We are delighted to bring you another episode in
the peripheral nerve podcast series understanding chemotherapy induced peripheral neuropathy.
In this episode we're so excited to welcome Assistant Professor Grace Shin from Ohio State University
Department of Neurology. Dr. Shin is a founding scientist at the Ohio State University CIPN clinic,
as well as the member of the Comprehensive Cancer Center at the Neuroscience Research Institute,
the Institute of Brain Behavior and Immunology, as well as the Department of Dermatology.
She previously undertook postdoctoral work focused on CIPN Translational Neuroscience at Columbia University.
Dr. Shin's group's work focuses on peripheral mechanisms of sensory neuro injury,
inflammation, and resilience in skin, using multiple methods across proclinical and clinical
settings. Today, we will discuss the topic of Neuromon Costolt and Information in chemotherapy
induced peripheral neuropathy. We are honored to have you here, speak with us today.
Yeah, thank you so much for inviting me. It's really an honor to be part of this series
and to have this opportunity to talk about neuroimmune mechanisms in CIPN.
To kick start our conversation, I would like to ask you what do we currently understand about
the Neuromon mechanism that drives CIPN, including any specific roles for the microglia and microphages.
This is an excellent question, because neuroinflammation is now considered one of the major
mechanisms contributing to CIPN. But I would like to start with an important caveat to this. Much of
what we know is still comes from preclinical models. Mouse and red studies have taught us great
deal, but we still have a more limited understanding of which neuroimmune mechanisms are most active
in patients. So, if we can start from the preclinical work, one of the best developed themes is
activation of innate immune signaling in and around the peripheral sensory nervous system.
Many studies have implicated TLR-4 related pathways, macrophages,
satellite glia cells and cytokines such as TNF-RFA, IL-6, and IL-1-Bira in multiple chemotherapy models.
They're also emerging studies on adaptive immune cells and systemic mortifiers such as
microbiome, but the most consistent evidence so far is still around innate immune responses.
So, one way to think about this is as biodeirectional neuroimmune crosstalk and amplification between
injure sensory neurons and non-neuronal cells. Chemotherapy may first stress or injure sensory neurons
and surrounding support cells, and that injury can release dangerous signals such as ATP and other
damage associated signals, which then activate nearby glial cells and immune cells. And these activated
macrophages and satellite glial cells can release cytokines and chemokines that recruit additional
immune cells and further sensitize sensory neurons. So, the immune response doesn't really simply sit
downstream of nerve injury, but once they're activated, it can run in peril with neuronal injury and
amplify and sustain nerve dysfunction. So, from the immune cell side, macrophages are one of the most
important and best studied periphery immune cell types in CIPN. They have been studied in the
doors of root ganglia, preferred nerve, and in a small number of studies, preferred tissues such as
skin. One thing that becomes very clear when you look at tissue closely is that macrophages are
a collection of cells with many different states and subcategories. This is something we think
about a lot in my lab. If you look at macrophages by subtype, activation state, and even by where
they're located relative to sensory axons, blood, assholes, or the vitamins, they can look and
behave very differently. And I think that this immediately changes the question. It's not really
simply our macrophage numbers increased, but whether which macrophage state and which tissue
compartment and at what time point is most relevant to CIPN. And that timing issue is something that
I would really emphasize, because macrophages are dynamic and heterogeneous. Their role may be very
different during early injury phase compared with the chronic phase or repair phase.
With the second cell type, microglia also appeared to be important, and a small number of studies
have shown that particularly when we're thinking about spinal cord mechanisms and sensory sensitization.
Studies suggest that the microactivation contributes to early pain signaling and long-term
changes in the central nervous system. But with all these cell types, the relative contribution of
macrophages that are likely to cells in microglia likely depends on chemotherapy agent and timing,
sex, model system, and whether we are studying acute pain, persistent pain or excellent
regeneration that may or may not be coupled with pain. So all together, I'll summarize in this
way. We now know that CIPN is not only a direct neurotoxicity problem, and chemotherapy can
activate innate immune pathways in and around sensory nervous system, often through injury signals
first generated by neurons, and there's a rounding micro apartment. So the next step is to
really understand which of these neuroimmune interactions that we study in pre-clinical models
actually do occur in patients and in which tissues and which stage of CIPN. And in my opinion,
most importantly, which of these neuroimmune changes are most relevant to symptom severity
and chronicity in the clinic. Thank you so much, Grace. Following up on that, if I could ask,
what do we currently know about changes in the skin environment, which might drive near inflammation
during neurotoxic chemotherapy treatment? Yeah, this is still an emerging and relatively under
developed area in CIPN, but this is actually one of the areas I find most exciting. Historically,
skin has often been treated mainly as the place where we measure intraepiderminerve fiber loss,
which is the loss of sensory nerve endings embedded in the epidermis. But as you can imagine,
skin is not a passive organ. Sensory nerve endings sit in close contact with
carcinocytes, fibroblast, vascular cells, and immune cells. So together, these cells form
an active neurocutaneous environment. And this is exactly why skin is so interesting to us.
In our work, we think about skin not only as a place to count nerve fibers, but as a neuronal
environment, microenvironment, where nerves, immune cells, and epicelial cells and best culture
are all interacting with one another. So when you look at it this way, the question becomes more
nuanced. It's not really only our nerve fibers lost, but it's also what kind of local tissue
environment are those nerve fibers losing contact with or whether they could still interact with.
So we don't really have enough studies showing exactly how chemotherapy models disembaram
in patients. But we can actually learn a great deal from inflammatory skin disease,
pain biology, and basic studies of neuro skin communication. So from those fields, I think
there are several plausible ways that the skin environment could contribute to your inflammation
during the IPN. So first scenario that I can think of is that the carcinocytes themselves may
respond to chemotherapy and alter sensory neuron function. This is the best area that has been
worked out, work from Stucky, Catarina, Visory, and Talogus, and other groups has really changed how
we think about carcinocytes. These cells can participate in treating sensory signaling through
mechanisms such as ATP signaling, on trip channel mediated sensory pathways, and direct
carcinocytes sensory neuron communication. And most recent workers extended this idea
in the CIPN field as well, where Pagletoxal induced mechanical hairpersensitivity through
PH1 was mediating changes in carcinocytes and contributing to the CIPN pathology.
And that was an important conceptual shift because it suggested that carcinocytes are not
just passive neighbors of sensory pendings but they may actively participate in sensory signaling
after chemotherapy. The second case that we can think about is nerve degeneration, nerve
degeneration itself may actually be modeled as skin environment. So if sensory fibers retract
from the epidermis, the loss of normal neuron to skin communication may trigger stress repair
or innate immune programs in the tissue. So inflammation may not only be the upstream of
nerve injury but also be a consequence of denurbation that feeds back onto the remaining
sensory nerve fibers. And finally, there may be direct immune modeling in the skin.
From other inflammatory skin and pain conditions, we
we know that cardinal size and fiberglass can produce cytokines and chemokines, and that
mast cells, macrophages, neutrophils, and other immune cells can shape local centering
nerve function.
In SAPIEN, this is still much less developed, but there is some evidence from human skin
biopsy studies suggesting local immune changes.
So altogether, the broad concept is that SAPIEN may involve pathological neurocutaneous niche.
It is not just injure neurons in isolation, but injure neurons interacting with remodel
skin environment, one that may include epithelial stress, fiberglass activation, vascular changes
and immune cell recruitment, and alter communication between skin cells and sensory nerve terminals.
I think this really matters because skin is clinically accessible and biologically active
organ, and it is directly connected to the sensory symptoms patients experience.
So by studying the skin environment more carefully, we may be able to understand not only where
nerve fibers are lost, but also how local neuro-neeming interactions contribute to ongoing
inflammation, pain, numbness, and sensory dysfunction in SAPIEN.
Thank you so much for this clear card overview.
It's coming out from this. Do you see that neuromont pathways offer potential biomarkers
or therapeutic approaches for SAPIEN?
Yes, I definitely think neuromont pathways offer potential biomarkers and therapeutic
approaches for SAPIEN, but at this stage, I would be cautious about oversimplifying this.
I don't think we're really at the point where one circulating cytokine can diagnose
SAPIEN or one inflammatory target will work for everyone.
So in preclinical models, inflammatory pathways are quite convincing.
We see changes in macrophages, glial cells, and cytokines, and these pathways can sensitize
neurons that may contribute to pain and longer term nerve dysfunction.
But when you look at the studies from patient cohort, plus by cytokine data are more mixed
than what we see in preclinical studies. And to be honest, I don't think that is really
surprising. Cancer patients are highly heterogeneous.
They are different in age, cancer type, chemotherapy exposure, and they have comorbidities.
They may have baseline inflammation, medications, and they may be also measured in a different
timing relative to treatment.
So with this in mind, I think the field needs to move toward a more patient informed biomarker
approach.
Instead of asking only whether one inflammatory marker is higher, we can ask whether certain
patients have a neuroinnovine or inflammatory state that maps onto symptoms, nerve injuries,
king pathology, or treatment response.
And I also think that the tissue biomarker can be very important.
Plasma is very useful because it is accessible and especially in the cancer treatment setting.
But it may not fully capture what is happening locally in Dorsal Look Anglia, Perfer Nerve
or Skin, which are the migraine environments of the neurons.
So of course, Dorsal Look Anglia and Perfer Nerves are not rarely accessible in most CIPM patients.
But skin biopsy is much more feasible. And as we discussed, it may help connecting the
circulating biomarkers with local neurocutaneous pathology, including nerve biverlose, immune
cell changes, and vescular remodeling and epithelial stress.
And this is very much aligned with how we think about this in my lab.
We don't think go like plasma versus tissue, but we aim to connect systemic biomarkers with
patient symptoms and local tissue biology.
Going back to that question for a more direct answer, there are putically, I think, immune
pathways are attracted.
But we need to be careful because of these cancer patients.
These are the cancer patients and cancer survivors.
Their disease and treatments are deeply intertwined with the immune system.
Immune responses can be damaging, but they can also participate in tissue repair, nerve
repair, and of course, anti-tumor immunity and treatment response.
So the goal should not be broad immune suppression, but rather identifying specific neuroimmune
pathway, timing, and immune cell state, where targeting the immune response makes sense
for patients.
And then knowing which patient subgroup that we can actually apply those to without compromising
cancer control or recovery.
So overall, in order to get to the stage of Bioball Neuroimmune Biomarkers in CIPN, I think
the next step is not simply measuring inflammation in patients, but it is understanding which immune
state belongs to which patient and which time point, and whether that immune state is driving
injury, repair, or more complex response to cancer treatment and nerve damage.
Thank you so much.
What experimental models do you think are critical for further understanding in this research
area?
And I suppose linking between this preclinical and clinical work, as you've mentioned.
Yeah, that's a great question.
I think more than models will continue to be essential for understanding this neuroimmacanisms,
especially because they allow us to study tissue-specific immune response, and genetic
tools are available, and we can measure behavior in ways that are difficult to apply in humans.
Mouse and rat models have already told us a great deal about this field in relation
to macrophages, cytokines, sensory neuron injury, and pain behavior.
I also like to add that the non-memelium model, such as zirrophician, yourself, can also
contribute.
There are simpler systems, but aspects of neuronal injury and stress response and innate
immunology, and chemotherapy toxicity are conserved as work from our lab and others have
shown.
These models can be powerful for rapid discovery and genetic screening, especially when they
are paired with mammalian and human systems.
But beyond the choice of model, I think one major need is better self-type resolution.
NCIPN studies describe broad myeloid cell or macrophage involvement, but that is almost
like talking about neurons as one category.
We know neurons include many subtypes with different functions, and same is true for
macrophages and other immune cells.
We need to understand which new cell subsets are involved in different steps of CIPN,
from initiation, progression, and generation pain and repair, and all the way to the transition
of chronic symptoms for some patients.
Other fields such as peripheral nerve injury and spinal cord injury have already developed
more detailed ways of thinking about immune cell heterogeneity.
So I think CIPN studies can benefit from adopting that level of rigor, especially if we want
to identify more specific targets that doesn't interfere with the cancer treatment.
In parallel, the field is moving towards patient-linked models. IPSC drive sensory neurons are being
used more often, and there is a lot to learn from patient plasma, peripheral blood, one
on nuclear cells, PBMCs, skin biopsy, and potentially patient-derived systems that can
include both sensory neurons in immune cells.
These approaches can help us model the patient-specific environment that determines why some individuals
develop severe CIPN and others do not.
I think this combination is very important to how we think about the problem in our own
work.
So using experimental systems, patient access for tissues, clinical information altogether.
These models are complementary, but they're not mutually exclusive.
M.O. models, cell culture systems, patient-derived models, and clinical data sets, I think, are
each answering different questions.
Across all of these systems, one major challenge that I see is that the model design really
matters.
Chimotherapy resumin, dose and rot, behavior SA, tissue, and time point can always shape
what we see.
That is especially important for immune response, because inflammatory readouts are often highly
context and time-dependent.
Some immune changes may be transient and occur early after chemotherapy exposure, so if
we only look at one late time point, and we may miss the most important window and the
reverse can be author true.
And this is the point that is lacking in many studies in the field in general to compensate
for that longitudinal animal and cell culture studies with carefully defined exposure conditions,
tissues, and time points will be critical.
And I think the same logic applies clinically.
I would include longitudinal clinical data set as part of model building process.
We need to understand not only what happens during chemotherapy or immediately after treatment,
but also what was happening before the treatment and how symptoms evolve over time.
So all together, I think the most important direction is back translation, especially
for neuroimmune studies.
I noticed this easier said than done, and even in our lab, we do not always aim to fully
recreate the complexity of the patient environment.
But rather, the goal is to identify which aspects of the environment are most relevant to
the question that we're asking.
Immune responses are strongly shaped by patient backgrounds such as age, comorbidity, prime
inflammation, and treatment history. And if we ignore that context, our model
may capture important mechanisms, but not necessarily the ones that explain why CIPM
becomes severe or chronic in real patients. So I think we should use clinical observation whenever
possible to build better models, not only asking whether pre-clinical findings can translate into
patients. Thank you so much. You really gave us a broad perspective. To conclude our conversation,
I would like to ask you what do you think is the most promising avenue in research in this field?
Yeah, I think one of the most promising avenues is to connect deep patient phenotyping with
mechanistic model systems in a much more intentional way. We have learned a great deal from pre-clinical
models and we still have a lot to learn, but many groups in this field are now thinking carefully
about how to connect those mechanistic insights back to what is actually happening in patients.
And as you would agree, CIPM is not one uniform condition. It differs by chemotherapy class,
cancer type, age, vulnerability, and baseline nerve cells, and importantly immune status.
So the field needs larger, well phenotype patient cores where we can integrate things we
discussed today, symptoms, functional outcomes, treatment exposure, plasma biomarker,
skin biopsy, and a possible longitudinal clinical data. I think that will allow us to define
biologically meaningful CIPM phenotypes rather than treating all patients as one group.
At the same time, we need more modeled systems that are informed by those patient data.
This is back translational point, I mentioned earlier. Instead of only asking whether animal
or cell culture findings can translate into humans, we should also back translate from human
observation into models. So if a subset of patients show a particular inflammatory
neurocutaneous or external injury signature, we can then ask mechanistically whether the signature
drives nerve dysfunction, pain, degeneration, or impaired repair that could compromise life
quality for these patients in the long term. And this is also where my lab aims to contribute to
the field. We aim to link careful clinical phenotyping, patient access for tissues like blood
and skin, and experimental models. Our goal is not to just characterize CIPM, but to understand
which mechanisms matter most for the patients we're trying to help. So I think neuroimmune pathways
in this way are especially promising because they may provide both shared and distinct mechanisms
across different cancer therapies. Different chemotherapy agents may initiate injuries through
different upstream mechanisms because they affect different cellular targets. But some of those
effects may converge on to targetable immune, inflammatory, or tissue remodeling pathways.
Several groups are approaching this from different angles and bringing these perspectives together
will be, I think it will be very important. And one unique opportunity in CIPM compared to other
types of nerve injury is that it is something in some ways predictable. We know when patients
are in neurotoxic therapy and that creates the possibility of identifying early immune or tissue
responses that predict later in your office and potentially intervening before chronic symptoms
become established. And many of us hope this will be one of the next meaningful advances we can
make for patients. But as you may understand that prevention may not be the only opportunity,
and indeed in cancer patients, prevention can be challenging because we have to avoid
interfering with effective cancer treatment. So we also need to understand the transition from
early chemotherapy induced injury to long-term inflammation, neuroinflammation, tissue remodeling,
and chronic symptoms. The immune response during active chemotherapy may be very different from
immune response years later in chronic CIPM. So those differences matter if we want to identify
the right target and the right therapeutic window. So considering all this,
ultimately I think the field is moving toward mechanism informed CIPM care,
which is identifying which biological pathways active in which patients and which stage of disease
and after which treatment exposure. So if we can do that as a field, I think we can move beyond
treating CIPM as a one broad toxicity and began developing more precise mechanism informed
strategies for prevention, monitoring, and intervention. Thank you so much Dr. Shinp for sharing
your insights and find relevant papers in the show notes and visit www.pnssociety.com for more
information about the peripheral nerve society. We'd also like to highlight the traumatic and toxic
neuropathy consortium, which is a special interest group of the peripheral nerve society.
The consortium encompasses pre-clinical and clinical experts from across the globe working together
to increase knowledge and fund solutions for toxic neuropathy such as CIPM, as well as traumatic
nerve damage. Please visit the PNS website for more information on how you can join the consortium.
Thank you for listening. See you next month.
The primary purpose of the peripheral nerve podcast is to meet the educational needs of
its listeners and address practice gaps by providing practice oriented and scientifically-based
education that will maintain an advanced competence and performance in the peripheral nerve field.
A diversity of opinions exists in the medical field and the views of the podcast faculty do not
represent those of the peripheral nerve society or constitute an endorsement by the peripheral
nerve society.
Podcast Summary
Key Points:
Neuroinflammation, particularly via innate immune pathways such as TLR-4, macrophages, and cytokines like TNF-α, IL-6, and IL-1β, plays a key role in chemotherapy-induced peripheral neuropathy (CIPN), though much evidence comes from preclinical models.
Macrophages and microglia are central to neuroimmune crosstalk in CIPN, with macrophage heterogeneity and dynamic states varying by tissue location, timing, and disease stage—highlighting the need for precise characterization.
The skin environment is actively involved in CIPN through neurocutaneous interactions, where cancer cells, immune cells, and epithelial stress can alter sensory neuron function and trigger inflammatory feedback loops.
While inflammatory biomarkers show promise, their clinical utility is limited by patient heterogeneity, and more patient-centered, phenotype-driven biomarker approaches are needed to link immune states to symptoms.
Tissue-based biomarkers, especially from skin biopsies, offer better insight into local neuroimmune changes than blood-based markers and can bridge preclinical findings with clinical reality.
Experimental models—including mice, zebrafish, and patient-derived systems—should be used in concert with clinical data to improve model relevance and identify patient-specific mechanisms.
A major research shift is toward patient phenotyping integrated with mechanistic models to define biologically distinct CIPN subtypes and tailor prevention and treatment strategies.
The field is moving toward mechanism-informed, stage-specific care by identifying which neuroimmune pathways drive early injury versus chronic symptoms, enabling timely and targeted interventions.
Summary:
Chemotherapy-induced peripheral neuropathy (CIPN) is increasingly understood as a neuroimmune disorder rather than purely a direct neurotoxic effect. Preclinical studies highlight the role of innate immune activation—particularly through macrophages and cytokines—driven by sensory neuron injury and resulting in bidirectional neuroimmune crosstalk. However, translating these findings to patients remains challenging due to variability in cancer types, treatment regimens, and baseline immune status.
The skin, once viewed merely as a site of nerve fiber loss, is now recognized as a dynamic neurocutaneous environment where cancer cells, immune cells, and epithelial stress contribute to inflammation and sensory dysfunction. , skin biopsies) offers a more meaningful pathway for diagnosis and monitoring. Research is shifting toward integrated models that combine preclinical data with longitudinal clinical observations to identify distinct CIPN subtypes.
Key advances will come from understanding how immune responses evolve over time—from acute injury to chronic symptoms—and developing targeted, stage-specific therapies that do not compromise cancer treatment efficacy. Ultimately, the field aims toward mechanism-informed, personalized approaches to CIPN care, enabling early prediction, prevention, and effective intervention based on individual patient biology.
FAQs
Neuroinflammation is a major driver of CIPN, primarily through innate immune signaling in and around sensory nerves. Chemotherapy injures sensory neurons, triggering the release of damage signals like ATP, which activate macrophages, satellite glial cells, and microglia. These activated immune cells release cytokines (e.g., TNF-α, IL-6, IL-1β) that amplify neuronal sensitization and sustain nerve dysfunction through bi-directional neuroimmune crosstalk.
Macrophages are the most studied peripheral immune cells in CIPN, particularly in root ganglia and skin, where they show dynamic activation states. Microglia play a role in central sensitization and early pain signaling. Both cell types are heterogeneous and their contributions depend on chemotherapy type, timing, sex, and disease stage. Their roles shift from early injury to chronic phases, indicating a complex, time-dependent involvement.
The skin is an active neurocutaneous environment where sensory nerves interact with immune cells, fibroblasts, and epithelial cells. Chemotherapy may alter skin cells (e.g., carcinoma cells) to activate sensory signaling via ATP or mechanosensitive pathways. Nerve degeneration itself may trigger tissue inflammation through stress and repair responses, and local immune cell activation (e.g., mast cells, macrophages) can further drive neuroinflammation and sensory dysfunction.
Yes, neuroimmune pathways show potential as biomarkers and therapeutic targets, but not universally. Circulating cytokines alone are insufficient due to patient heterogeneity. More promising are patient-specific biomarker profiles linked to symptoms and tissue changes. Targeting specific immune states—rather than broad suppression—is safer and more effective, especially in balancing cancer treatment with nerve protection.
Mouse and rat models are essential for studying tissue-specific immune responses and pain behaviors. Non-mammalian models (e.g., zebrafish) offer rapid genetic screening. However, better models include patient-derived systems (e.g., iPSCs), skin biopsies, and longitudinal studies that account for timing, dose, and immune context. These models help bridge preclinical findings to patient-specific outcomes.
Deep patient phenotyping—integrating symptoms, treatment exposure, plasma biomarkers, and skin biopsy data—can identify distinct CIPN subtypes. This allows for mechanism-informed care, where therapies are tailored to individual immune and tissue profiles. It also enables early prediction of severe symptoms and supports targeted prevention or intervention before chronicity develops.
Chat with AI
Loading...
Pro features
Go deeper with this episode
Unlock creator-grade tools that turn any transcript into show notes and subtitle files.